VNU, IMS look for way out of deal: WSJ

Share this article:
Dutch publishing giant VNU is locked in a stalemate with U.S. pharmaceutical research company IMS Health over how to terminate its $7 billion planned acquisition of IMS, The Wall Street Journal reported today.
Holders of nearly half of VNU's shares have said they would turn down the plan to buy IMS, forcing VNU to find a way to abandon its agreed purchase of IMS.
After holding talks, the two companies can't agree on terms to end the deal, the newspaper reported.
VNU said early today that it is "having wide ranging discussions with IMS" to address the development.
In a statement, VNU said that "although both companies continue to believe the transaction, as negotiated, is in the best interests of their respective shareholders, the companies have discussed various possible alternatives, including a revised merger agreement as well as termination of the agreement."
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.